Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - Sensei's lead product candidate is solnerstotug, designed to block the VISTA checkpoint selectively in the tumor microenvironment [3] Company Overview - Sensei Biotherapeutics operates through its TMAb™ platform, which develops conditionally active therapeutics to target immunosuppressive signals in tumors [3] - The company's approach aims to activate T cells against tumors by selectively disabling immunosuppressive mechanisms [3] Event Details - John Celebi, President and CEO of Sensei, will present at the conference virtually at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website for approximately 90 days post-event [2]

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment, aiming to enhance T cell activity against tumors [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment, which is crucial for T cell activation [3] Upcoming Events - John Celebi, President and CEO of Sensei Biotherapeutics, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days post-event [2]

Core Insights - Sensei Biotherapeutics is advancing its lead program, solnerstotug (SNS-101), which targets the immune checkpoint VISTA, with expectations for significant clinical data updates in 2025 [1][2][4] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients, utilizing its TMAb™ platform to create conditionally active therapeutics [4][5] Product Development - Solnerstotug (SNS-101) is designed to selectively target VISTA within the tumor microenvironment, which is associated with low survival rates in various cancer types [3][4] - The company is conducting a multi-center Phase 1/2 clinical trial to evaluate solnerstotug's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4][5] Clinical Trial Progress - As of January 1, 2025, 45 patients have been enrolled in the dose expansion portion of the trial, with an expected total of approximately 60 patients by the end of Q1 2025 [5] - The company anticipates reporting data from evaluable patients in Q2 2025, including follow-up data from dose escalation cohorts [5] Financial Position - Sensei Biotherapeutics has a cash runway projected into the second quarter of 2026, allowing for the advancement of solnerstotug through the completion of the Phase 1 portion of the study [2][5]

Core Insights - Sensei Biotherapeutics is advancing the clinical development of SNS-101, with Phase 1/2 dose expansion clinical data expected in the first half of 2025 [1][5] - The company is undergoing organizational restructuring to focus resources on SNS-101, which includes a workforce reduction of approximately 46% [2][6] - The cash runway has been extended into the second quarter of 2026, with cash, cash equivalents, and marketable securities totaling $47.0 million as of September 30, 2024 [1][7] Clinical Development - SNS-101 is a conditionally active antibody targeting the immune checkpoint VISTA, which is associated with low survival rates in various cancer indications [3] - The Phase 1/2 clinical trial is evaluating SNS-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD1 inhibitor Libtayo® [4] - Patient enrollment in the dose expansion portion of the study is progressing, with approximately half of the study enrolled [5] Financial Performance - Research and Development (R&D) expenses for Q3 2024 were $4.6 million, an increase from $3.8 million in Q3 2023, primarily due to higher clinical trial costs [8] - General and Administrative (G&A) expenses decreased to $3.2 million in Q3 2024 from $3.9 million in Q3 2023, attributed to lower insurance premiums and outside services [9] - The net loss for Q3 2024 was $7.3 million, slightly higher than the $7.1 million loss in Q3 2023 [9][11] Corporate Updates - The company is closing its research site in Rockville, Maryland, as part of its restructuring efforts [6] - Josiah Craver was appointed as Senior Vice President, Finance, and later as the principal financial officer [6] - Sensei presented data on SNS-101 at various industry conferences, including PEGS Europe and the Society of Immunotherapy Cancer Annual Meeting [5]

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage company focused on developing next-generation therapeutics for cancer patients [1] - The company will present at two scientific conferences in November 2024, showcasing its innovative research in cancer therapies [1] Conference and Presentation Details - Sensei Biotherapeutics will present at the PEGS Europe: Protein and Antibody Engineering Summit from November 5-7, 2024, in Barcelona, Spain [1] - The presentation titled "Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody" will be delivered by Dr. Edward van der Horst on November 5, 2024, at 9:00 a.m. CET [1] - The company will also present at the Society for Immunotherapy Cancer (SITC) 39th Annual Meeting from November 6-10, 2024, in Houston, Texas [1] - The poster presentation titled "Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications" will be presented by Dr. F. Donelson Smith on November 9, 2024, during two sessions [1] Company Overview - Sensei Biotherapeutics utilizes its TMAb™ (Tumor Microenvironment Activated biologics) platform to develop conditionally active therapeutics [1] - The lead investigational candidate, SNS-101, is designed to block the VISTA checkpoint selectively within the low pH tumor microenvironment [1] - The company is also developing additional candidates, including SNS-102, SNS-103, and SNS-201, targeting various immunosuppressive signals in the tumor microenvironment [1]

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage immuno-oncology company focused on developing next-generation therapeutics for cancer patients [2] Group 1: Upcoming Conferences - Company management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET [1] - The company will also participate in the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18, 2024, at 2:30 p.m. ET [1] - Webcasts of both presentations will be available on the Investors section of the Sensei website for approximately 90 days following the events [1] Group 2: Product Development - Sensei Biotherapeutics utilizes its TMAb™ platform to develop conditionally active therapeutics that target the tumor microenvironment [2] - The lead investigational candidate, SNS-101, is designed to block the VISTA checkpoint selectively within the low pH tumor microenvironment [2] - Other candidates in development include SNS-102 targeting VSIG-4, SNS-103 targeting ENTPDase1 (CD39), and SNS201, a bispecific antibody combining CD28 agonist and anti-VISTA components [2]

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial re ...

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial re ...

Core Insights - Sensei Biotherapeutics' stock (NASDAQ:SNSE) is experiencing a significant decline following disappointing Phase 1/2 clinical trial results for its drug SNS-101, which targets the immune checkpoint VISTA for treating solid tumors [1][2] Clinical Trial Results - In the recent trial, only a few out of 34 patients treated with SNS-101 showed signs of improvement, leading to negative reactions from investors [2] - Dr. Shiraj Sen, a principal investigator, noted that the data revealed encouraging signs of clinical activity in a diverse group of patients with advanced solid tumors, particularly in cases where clinical responses are typically not expected, such as microsatellite stable colorectal and endometrial tumors [3] Stock Market Performance - As of Friday morning, SNSE stock has dropped by 39.8%, although it had previously increased by 83.5% year-to-date before the latest market close [4] - The trading volume for SNSE stock on Friday morning exceeded 160,000 shares, approaching its daily average of approximately 208,000 shares [3]

Core Insights - Sensei Biotherapeutics reported promising clinical data for SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, showing initial signs of clinical activity in advanced solid tumors [1][10] Clinical Trial Overview - The Phase 1/2 trial of SNS-101 includes a dose escalation portion to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [3][4] - A total of 34 patients participated, with 16 in the monotherapy arm and 18 in the combination arm, where 85% had tumor types typically unresponsive to PD-1 monotherapy [4] Clinical Activity and Efficacy - Preliminary data indicated promising clinical activity across multiple tumor types, including microsatellite stable colorectal and endometrial tumors, which usually show low response rates to existing immunotherapies [2][4][10] - Specific cases included a 59% decrease in tumor size for an endometrial cancer patient and 27% regression for a colorectal cancer patient, both receiving SNS-101 in combination with cemiplimab [8] Safety and Tolerability - SNS-101 was well tolerated, with no dose-limiting toxicities observed; most adverse events were Grade 1 or 2 [6][10] - Two patients experienced mild Grade 1 cytokine release syndrome, indicating manageable side effects [6][9] Pharmacokinetics - SNS-101 demonstrated a potentially best-in-class pharmacokinetic profile with linear elimination kinetics and dose-proportional increases in exposure, supporting the once every three weeks dosing regimen [5][10] Future Developments - The company is advancing to the dose expansion portion of the trial and expects to report initial data by the end of 2024, along with an end-of-Phase 1 meeting with the FDA [11] - Data will be presented at the 2024 ASCO Annual Meeting on June 1, 2024 [12]